Nicaragua Regulatory Timeline and Adenda 2026-05

1. Key takeaways

Nicaraguan device regulation changed generation twice within the three years from 2023 to 2026. On 21 October 2024, NTON 24001:2023 was published in La Gaceta No. 192; Chapter 16 provides that it enters into force ninety days after publication, and Chapter 14 repeals four earlier instruments at once, including Norma 064. During 2025 and 2026, three administrative resolutions moved the sanitary licence, the sanitary registration, the import authorisation and five categories of authorisation entirely online, through Karplus and VUCEN. In 2026, Adenda 2026-05 (Ad.01) entered public consultation, with the consultation period running to 1 July 2026.

• The rule book was replaced first, in 2024, and the filing channels second, in 2025 and 2026.
• Chapter 14 repeals four earlier instruments at once, with no transition period in the text.
• Signed dates and effective dates differ for two of the three resolutions and coincide for the third.
• Chapter 16 makes the entry into force a calculation from publication, not a fixed calendar date.
• Adenda 2026-05 would add a SaMD definition and revise the drug-device combination test.
• Nothing in the addendum is a current requirement until it is finalised.

2. Legal basis

The table lists the instruments in chronological order, together with the provisions that fix their dates and scope.

3. Expert insights

The first point is the sequence. The first change of generation replaced the rule book, with NTON 24001 substituting for Norma 064 in its entirety. The second replaced the filing channel, with three administrative resolutions moving processes online. Rules first and channels second is the rhythm that matters most in this market, and it explains why 2025 and 2026 produced a run of purely procedural resolutions.

The second point is the completeness of the repeal. Chapter 14 removes four instruments at once, and Norma 064 had been in force since 5 May 2011 until NTON took effect. The text provides no transition period, so the old rule set exits as a whole. Filing experience built before 2024 therefore largely ceases to be valid, which is a practical rather than a theoretical loss.

The third point is dates. None of the three resolutions has an effective date equal to its signature date, and the gaps are not the same: RA 0007/2025 was signed on 22 April 2025 and took effect on 2 May 2025, ten days later; RA 0020/2025 was signed on 2 October 2025 and took effect on 13 October 2025, eleven days later; RA 0001/2026 was signed and took effect on 5 February 2026, the same day. Citations must state each date separately, and quoting only the year is not sufficient.

The fourth point is the entry into force of NTON itself. The ninety-day rule in Chapter 16 makes the effective date a calculation from publication rather than a published date. The publication vehicle verified for this guide is La Gaceta No. 192 of 21 October 2024; the exact calendar date of entry into force is a matter for the official publication, and this guide does not calculate it. That gap is deliberate.

The fifth point is clause 5.11 of Ad.01, the most substantive proposed change: drug-device combinations would move from a choice between primary modes of action to treatment according to each mode of action, and the verification duty would be qualified by “según aplique”, meaning as applicable. The consultation runs to 1 July 2026 and the text does not constitute a current requirement before it is finalised.

The sixth point is the new SaMD definition in Chapter 4 of Ad.01, with seven notes, which pairs with the software classification in rule 11 of Annex B. This is the area least covered by Chinese-language material so far, and it is the provision that software companies should track most closely.

4. Practical recommendations

• Maintain an annual regulatory watch that lists NTON 24001, the three administrative resolutions, the two circulars and Ad.01 separately.
• Cite administrative resolutions with both the signature date and the effective date rather than only the year, since the three resolutions have different gaps.
• Set the finalisation of Adenda 2026-05 as a quarterly review item: the consultation runs to 1 July 2026, and the compliance route for combination products and software devices should be reassessed once it is final.
• Do not rely on filing experience from before 2024, since Chapter 14 repealed Norma 064 and the other three instruments at once.
• Take the NTON effective date from the official publication rather than calculating a calendar date from the ninety-day rule.
• Include the accounts, modules and quota status of the Karplus and VUCEN platforms in the annual review.

5. Verification checklist

• □ The annual regulatory watch covers NTON 24001, the three administrative resolutions, the two circulars and Ad.01.
• □ Signature dates and effective dates of the administrative resolutions are recorded separately.
• □ The finalisation status of Adenda 2026-05 is a quarterly review item.
• □ Filing experience based on Norma 064 before 2024 is not in use.
• □ The NTON effective date is taken from the official publication and not calculated.
• □ Karplus and VUCEN accounts, modules and quotas are included in the annual review.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com